PAHC · XBRL financial data

Phibro Animal Health financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PAHC's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Revenue from contracts with customers	231	250	263	273*	260	309	348	379*	364	374	384	397*
Cost of goods and services sold	164	171	184	186*	177	207	243	269*	244	241	258	262*
Gross profit	68	79	80	87*	83	102	105	110*	120	133	126	134*
Research and development	—	—	—	year only	—	—	—	year only	—	—	—	year only
Selling, general and administrative	68	63	60	69*	66	76	71	76*	69	82	81	86*
Operating income (loss)	(1)	16	20	18*	18	26	34	34*	51	50	45	48*
Interest expense	6	6	6	6*	9	10	10	9*	13	12	11	11*
Income tax expense (benefit)	(4)	2	5	6*	3	2	9	7*	10	9	8	11*
Net income (loss)	(8)	1	8	1*	7	3	21	17*	27	27	24	22*
Earnings per share, basic USD per share	(0.20)	0.03	0.21	0.02*	0.17	0.08	0.52	0.42*	0.65	0.68	0.59	0.54*
Earnings per share, diluted USD per share	(0.20)	0.03	0.21	0.02*	0.17	0.08	0.51	0.42*	0.65	0.67	0.59	0.53*
Weighted average shares, basic millions of shares	41	41	41	41*	41	41	41	41*	41	41	41	41*
Weighted average shares, diluted millions of shares	41	41	41	41*	41	41	41	41*	41	41	41	41*

Fiscal quarters (PAHC's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Cash and cash equivalents	43	33	50	71	52	67	60	68	73	55	55	61
Short-term investments	48	60	49	44	38	0	10	9	13	19	23	21
Accounts receivable	149	151	161	169	161	192	198	228	218	216	222	239
Inventory	279	287	282	266	273	427	448	444	472	517	540	535
Total current assets	584	587	597	601	571	746	776	811	836	862	894	936
Property and equipment, net	193	201	202	203	206	338	336	355	355	355	359	369
Right-of-use asset	36	38	37	38	38	37	42	41	40	39	49	52
Goodwill	53	55	55	55	55	55	55	60	60	60	60	60
Total assets	965	973	979	982	966	1,286	1,317	1,361	1,386	1,406	1,445	1,501
Accounts payable	77	86	83	86	87	99	132	138	131	133	130	127
Current portion of long-term debt	24	26	—	30	8	16	16	16	18	21	23	—
Total current liabilities	172	188	189	204	177	233	266	293	270	282	282	316
Long-term debt	305	298	291	282	288	623	619	615	610	604	598	—
Lease liability, non-current	29	31	30	30	30	28	34	34	33	33	43	45
Total liabilities	691	702	709	726	708	1,039	1,051	1,075	1,074	1,073	1,083	1,116
Retained earnings	248	244	248	244	246	244	260	273	294	317	336	353
Total stockholders' equity	273	271	270	257	259	247	266	286	312	332	362	385
Total liabilities and equity	965	973	979	982	966	1,286	1,317	1,361	1,386	1,406	1,445	1,501

Fiscal quarters (PAHC's year ends in late June)

In millions of dollars	Q1 FY24Sep 30, 2023	Q2 FY24Dec 31, 2023	Q3 FY24Mar 31, 2024	Q4 FY24Jun 30, 2024	Q1 FY25Sep 30, 2024	Q2 FY25Dec 31, 2024	Q3 FY25Mar 31, 2025	Q4 FY25Jun 30, 2025	Q1 FY26Sep 30, 2025	Q2 FY26Dec 31, 2025	Q3 FY26Mar 31, 2026	Q4 FY26Jun 30, 2026
Net income (loss)	(8)	1	8	1*	7	3	21	17*	27	27	24	22*
Stock-based compensation	0	0	0*	0*	0	0*	0*	0*	0	0*	0*	0*
Depreciation and amortization	9	9	9	9*	9	12	13	12*	13	13	12	13*
Net cash from operating activities	16	32*	11*	28*	13	3*	43*	21*	9	19*	16*	24*
Net cash from investing activities	(15)	(25)*	1*	(9)*	(3)	(260)*	(18)*	(7)*	(21)	(17)*	(17)*	(16)*
Dividends paid	5	5*	5*	5*	5	5*	5*	5*	5	5*	5*	5*
Net cash from financing activities	1	(15)*	5*	2*	(29)	276*	(32)*	(8)*	16	(19)*	(2)*	(2)*
Net change in cash	2	(10)*	17*	20*	(19)	15*	(7)*	8*	5	(17)*	(1)*	6*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Phibro Animal Health	61	397*	24*	not reported	—	Q4 FY26 10-KJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	67	30	2.8*	79.1M	—	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.